New Approaches To Neuroblastoma Therapy Consortium
Clinical trials sponsored by New Approaches To Neuroblastoma Therapy Consortium, explained in plain language.
-
Immune cells take on childhood cancer in early trial
Disease control OngoingThis early-phase trial tests whether giving children with relapsed neuroblastoma their own expanded natural killer (NK) cells along with the drug dinutuximab is safe and feasible. Some children may also receive lenalidomide. The study involves 13 participants aged up to 30 years …
Phase: PHASE1 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail aims to fight tough childhood cancer
Disease control OngoingThis early-stage trial tests a combination of three drugs—sorafenib, cyclophosphamide, and topotecan—in children and young adults with neuroblastoma that has relapsed or not responded to treatment. The main goal is to find the highest safe dose of sorafenib when given with the tw…
Phase: PHASE1 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Precision medicine trial maps genetic clues in hard-to-treat childhood cancer
Knowledge-focused OngoingThis study looks at tumor samples from children and young adults (ages 1 to 30) with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to find specific genetic changes and immune system markers that could guide future treatments. No new therapy…
Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC